Revolade is an oral treatment that stimulates the production of blood platelets, which are essential to normal clotting.
GSK claimed that the anti-allergic drug, Xyzal, has been approved for the treatment of allergic rhinitis, urticaria, eczema and dermatitis, prurigo and cutaneous pruritus in patients over the age of seven years.
GSK Japan president Philippe Fauchet said that the approvals were very important to the company as they demonstrate the progress they are making in gaining approvals in Japan.